TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse Beloud

@businesswire.com · 8 hours

TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse

The TROPION-Lung12 phase 3 trial has officially begun, with the first patient receiving DATROWAY® (datopotamab deruxtecan) as part of an adjuvant regimen for patients diagnosed with early-st...

Read more Businesswire.com